LOS ANGELES (Reuters) - Ariad Pharmaceuticals' experimental cancer drug may improve overall survival in patients with advanced sarcoma, according to data from a phase III trial released Wednesday.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Sarcoma drug ridaforolimus may improve survival

Newsletter